multiple sclerosis
-
Once-monthly Zinbryta™ (Daclizumab) approved in European Union for treatment of Multiple Sclerosis
Aug 9, 2016News Hour: The European Commission (EC) has granted marketing authorization for ZINBRYTA™ (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced last month....
